Sphingolipids: Basic Science and Drug Development PDF
Preview Sphingolipids: Basic Science and Drug Development
Handbook of Experimental Pharmacology 215 Erich Gulbins Irina Petrache Editors Sphingolipids: Basic Science and Drug Development Handbook of Experimental Pharmacology Volume 215 Editor-in-Chief F.B. Hofmann, München Editorial Board J.E. Barrett, Philadelphia J. Buckingham, Uxbridge V.M. Flockerzi, Homburg D. Ganten, Berlin P. Geppetti, Florence M.C. Michel, Ingelheim P. Moore, Singapore C.P. Page, London W. Rosenthal, Berlin For furthervolumes: http://www.springer.com/series/164 . Erich Gulbins (cid:129) Irina Petrache Editors Sphingolipids: Basic Science and Drug Development Editors ErichGulbins IrinaPetrache DepartmentofMolecularBiology DivisionofPulmonary,Allergy, UniversityofDuisburg-Essen CriticalCareandOccupationalMedicine Essen DepartmentofMedicine Germany IndianaUniversitySchoolofMedicine Indianapolis,IN,USA ISSN0171-2004 ISSN1865-0325(electronic) ISBN978-3-7091-1367-7 ISBN978-3-7091-1368-4(eBook) DOI10.1007/978-3-7091-1368-4 SpringerHeidelbergNewYorkDordrechtLondon LibraryofCongressControlNumber:2013935698 #Springer-VerlagWien2013 Thisworkissubjecttocopyright.AllrightsarereservedbythePublisher,whetherthewholeorpart of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation,broadcasting,reproductiononmicrofilmsorinanyotherphysicalway,andtransmissionor informationstorageandretrieval,electronicadaptation,computersoftware,orbysimilarordissimilar methodologynowknownorhereafterdeveloped.Exemptedfromthislegalreservationarebriefexcerpts inconnectionwithreviewsorscholarlyanalysisormaterialsuppliedspecificallyforthepurposeofbeing enteredandexecutedonacomputersystem,forexclusiveusebythepurchaserofthework.Duplication ofthispublicationorpartsthereofispermittedonlyundertheprovisionsoftheCopyrightLawofthe Publisher’s location, in its current version, and permission for use must always be obtained from Springer.PermissionsforusemaybeobtainedthroughRightsLinkattheCopyrightClearanceCenter. ViolationsareliabletoprosecutionundertherespectiveCopyrightLaw. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publicationdoesnotimply,evenintheabsenceofaspecificstatement,thatsuchnamesareexempt fromtherelevantprotectivelawsandregulationsandthereforefreeforgeneraluse. While the advice and information in this book are believed to be true and accurate at the date of publication,neithertheauthorsnortheeditorsnorthepublishercanacceptanylegalresponsibilityfor anyerrorsoromissionsthatmaybemade.Thepublishermakesnowarranty,expressorimplied,with respecttothematerialcontainedherein. Printedonacid-freepaper SpringerispartofSpringerScience+BusinessMedia(www.springer.com) Preface Untilthelate1980s,sphingolipidswerebelievedtorepresentstructuralcomponents oftheplasmamembrane,whosefunctionwastoprovideaprotectivebarriertothe cell.Thispicturedramaticallychangedwithinthelastyears.Sphingolipidsarenow recognized signals for fundamental cellular processes, such as proliferation, sur- vival, cell death, adhesion, migration, angiogenesis, and embryogenesis. The explosion of knowledge regarding sphingolipids was facilitated by biochemical studies of their signaling properties, the cloning of enzymes of the sphingolipid metabolism, development of genetic models for determining their physiologic roles, and the establishment of biochemical, biophysical, and optical methods for theirdetectionandquantitation.Thenextstepintheevolutionofsphingolipidswill be the transfer of basic insights into the biochemistry and cell biology of human diseases.Therecentsuccessofthesphingolipiddrug,fingolimod,asphingosine-1- phosphate agonist, which rapidly became a therapy for multiple sclerosis, exemplifies the potential of targeting sphingolipids for the treatment of human disorders.Theaimofourtwovolumesinthisseries—Sphingolipds:BasicScience andDrugDevelopmentandSphingolipidsinDisease—istodefinethestateofthe art of sphingolipid biology and to present preclinical developments and early clinicalapplicationsofthisfascinatingclassoflipids. Essen,Germany ErichGulbins Indianapolis,IN,USA IrinaPetrache v . Contents PartI BasicMechanisms TheGeneticsofSphingolipidHydrolasesandSphingolipidStorage Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 EdwardH.SchuchmanandCalogeraM.Simonaro SphingolipidsandMembraneDomains:RecentAdvances. . . . . . . . . . . 33 SalvatoreChiantiaandErwinLondon SphingolipidMetabolismandNeutralSphingomyelinases. . . . . . . . . . . 57 MichaelV.AirolaandYusufA.Hannun AcidSphingomyelinase. . .. . .. . . .. . . .. . . .. . . .. . . .. . .. . . .. . . .. 77 BrianHenry,ReganZiobro,KatrinAnneBecker,RichardKolesnick, andErichGulbins CeramideSynthases:ReexaminingLongevity. . . . . . . . . . . . . . . . . . . . 89 Joo-WonParkandYaelPewzner-Jung MembraneChannelsFormedbyCeramide. . . . . . . . . . . . . . . . . . . . . . 109 MarcoColombini GeneticDisordersofSimpleSphingolipidMetabolism. . . . . . . . . . . . . . 127 VirginieAlbinet,Marie-LiseBats,CarmenBedia,Fre´de´riqueSabourdy, VirginieGarcia,BrunoSe´gui,NathalieAndrieu-Abadie,ThorstenHornemann, andThierryLevade TheRoleofCeramide-1-PhosphateinBiologicalFunctions. . . . . . . . . . 153 L.AlexisHoeferlin,DayanjanS.Wijesinghe,andCharlesE.Chalfant vii viii Contents PartII DrugDevelopment FunctionalInhibitorsofAcidSphingomyelinase(FIASMAs). . . . . . . . . 169 JohannesKornhuber,PhilippTripal,ErichGulbins,andMarkusMuehlbacher NovelDrugsTargetingSphingolipidMetabolism. . . . . . . . . . . . . . . . . . 187 KrishnaP.BhabakandChristophArenz TheTherapeuticPotentialofNanoscaleSphingolipid Technologies. . . . . .. . . . . . . . .. . . . . . . . . .. . . . . . . . .. . . . . . . . . .. . 197 JodyL.Hankins,UshmaA.Doshi,JeremyK.Haakenson,MeganM.Young, BrianM.Barth,andMarkKester NovelChemotherapeuticDrugsinSphingolipid CancerResearch. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211 DanielCanalsandYusufA.Hannun PharmacologyoftheSphingosine-1-PhosphateSignalling System. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239 DagmarMeyerzuHeringdorf,KatjaIhlefeld,andJosefPfeilschifter Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255 Part I Basic Mechanisms
The list of books you might like
